[go: up one dir, main page]

PL2929880T3 - A therapeutic agent for treating a disease that has an inhibitory effect on a factor that inhibits macrophage migration - Google Patents

A therapeutic agent for treating a disease that has an inhibitory effect on a factor that inhibits macrophage migration

Info

Publication number
PL2929880T3
PL2929880T3 PL14826811T PL14826811T PL2929880T3 PL 2929880 T3 PL2929880 T3 PL 2929880T3 PL 14826811 T PL14826811 T PL 14826811T PL 14826811 T PL14826811 T PL 14826811T PL 2929880 T3 PL2929880 T3 PL 2929880T3
Authority
PL
Poland
Prior art keywords
disease
treating
factor
therapeutic agent
inhibitory effect
Prior art date
Application number
PL14826811T
Other languages
Polish (pl)
Inventor
Keiichi Tanaka
Kimiko Morimoto
Original Assignee
Toyama Chemical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyama Chemical Co., Ltd. filed Critical Toyama Chemical Co., Ltd.
Publication of PL2929880T3 publication Critical patent/PL2929880T3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/24Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
PL14826811T 2013-07-18 2014-07-17 A therapeutic agent for treating a disease that has an inhibitory effect on a factor that inhibits macrophage migration PL2929880T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013149690 2013-07-18

Publications (1)

Publication Number Publication Date
PL2929880T3 true PL2929880T3 (en) 2017-03-31

Family

ID=52346269

Family Applications (2)

Application Number Title Priority Date Filing Date
PL16169414T PL3078372T3 (en) 2013-07-18 2014-07-17 Therapeutic agent for disease based on inhibitory effect of macrophage migration inhibitory factor
PL14826811T PL2929880T3 (en) 2013-07-18 2014-07-17 A therapeutic agent for treating a disease that has an inhibitory effect on a factor that inhibits macrophage migration

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL16169414T PL3078372T3 (en) 2013-07-18 2014-07-17 Therapeutic agent for disease based on inhibitory effect of macrophage migration inhibitory factor

Country Status (22)

Country Link
US (3) US20150353519A1 (en)
EP (2) EP3078372B1 (en)
JP (2) JP5802868B2 (en)
CN (1) CN105407887B (en)
AU (1) AU2014291149B2 (en)
CA (1) CA2918325C (en)
CY (2) CY1118140T1 (en)
DK (2) DK3078372T3 (en)
ES (2) ES2642440T3 (en)
HR (2) HRP20161317T1 (en)
HU (2) HUE034661T2 (en)
IL (1) IL243550B (en)
LT (2) LT3078372T (en)
NO (1) NO3078372T3 (en)
PL (2) PL3078372T3 (en)
PT (2) PT2929880T (en)
RS (2) RS56489B1 (en)
RU (2) RU2641301C2 (en)
SI (2) SI3078372T1 (en)
SM (3) SMT201700080T1 (en)
TW (1) TWI603965B (en)
WO (1) WO2015008827A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018137708A1 (en) * 2017-01-26 2018-08-02 重庆莱美药业股份有限公司 Nanocarbon-iron composite system, composition, preparation method, and application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0753725B2 (en) * 1987-10-08 1995-06-07 富山化学工業株式会社 4H-1-benzopyran-4-one derivative and its salt, their production method and anti-inflammatory agent containing them
US5922755A (en) * 1993-04-09 1999-07-13 Toyama Chemical Co., Ltd. Immunomodulator, cell adhesion inhibtor, and agent for treating, and preventing autoimmune diseases
EP0868598B1 (en) * 1995-12-21 1999-10-27 Siemens Aktiengesellschaft Air intake device with variable intake pipe length for an internal combustion engine
DE10044091A1 (en) * 2000-09-07 2002-04-04 Merck Patent Gmbh chromanone
GB0507695D0 (en) 2005-04-15 2005-05-25 Novartis Ag Organic compounds
GB0507696D0 (en) * 2005-04-15 2005-05-25 Novartis Ag Organic compounds
EP1940382A2 (en) * 2005-10-07 2008-07-09 Aditech Pharma AB Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
KR101722432B1 (en) 2011-08-30 2017-04-04 토야마 케미칼 컴퍼니 리미티드 Method for improving therapy for autoimmune diseases such as rheumatoid arthritis

Also Published As

Publication number Publication date
RU2016105141A (en) 2017-08-23
SI2929880T1 (en) 2016-12-30
IL243550A0 (en) 2016-02-29
AU2014291149B2 (en) 2017-05-04
IL243550B (en) 2019-06-30
AU2014291149A1 (en) 2016-02-11
DK2929880T3 (en) 2017-01-02
PL3078372T3 (en) 2018-02-28
RU2641301C2 (en) 2018-01-17
TWI603965B (en) 2017-11-01
ES2593527T3 (en) 2016-12-09
PT2929880T (en) 2016-11-08
LT2929880T (en) 2016-11-25
US9918963B2 (en) 2018-03-20
HK1222556A1 (en) 2017-07-07
SMT201700606T1 (en) 2018-01-11
TW201536764A (en) 2015-10-01
CA2918325C (en) 2018-06-26
HRP20171497T1 (en) 2017-11-17
EP3078372A1 (en) 2016-10-12
LT3078372T (en) 2017-11-27
RU2017131951A3 (en) 2020-12-18
JP6060231B2 (en) 2017-01-11
CY1119496T1 (en) 2018-03-07
EP3078372B1 (en) 2017-09-13
HUE034661T2 (en) 2018-02-28
NO3078372T3 (en) 2018-02-10
SMT201700080T1 (en) 2017-03-08
JPWO2015008827A1 (en) 2017-03-02
HUE029800T2 (en) 2017-04-28
CY1118140T1 (en) 2017-06-28
DK3078372T3 (en) 2017-10-16
RU2017131951A (en) 2019-02-06
EP2929880A1 (en) 2015-10-14
PT3078372T (en) 2017-10-18
JP2016034953A (en) 2016-03-17
US20160228404A1 (en) 2016-08-11
CA2918325A1 (en) 2015-01-22
CN105407887A (en) 2016-03-16
RU2750540C2 (en) 2021-06-29
SMT201700080B (en) 2017-03-08
CN105407887B (en) 2018-09-04
JP5802868B2 (en) 2015-11-04
EP2929880A4 (en) 2015-10-14
SI3078372T1 (en) 2018-01-31
US20160228406A1 (en) 2016-08-11
ES2642440T3 (en) 2017-11-16
US20150353519A1 (en) 2015-12-10
EP2929880B1 (en) 2016-09-14
RS56489B1 (en) 2018-01-31
RS55394B1 (en) 2017-04-28
HRP20161317T1 (en) 2016-12-16
WO2015008827A1 (en) 2015-01-22

Similar Documents

Publication Publication Date Title
CY2023027I2 (en) PYRIMIDINODIONE COMPOUNDS AGAINST HEART DISEASE
EP3954536C0 (en) MULTILAYER TISSUE REPLACEMENT MATRIX
HUE046596T2 (en) Methods for treating mitochondrial disease
IL256206A (en) mct4 inhibitors to treat the disease
LT3563837T (en) THERAPY FOR BACTERIOPHAGA
BR302014001196S1 (en) Medical Applied Configuration
LT3046537T (en) HYDROCARBONIC PHARMACEUTICAL FORM FOR THERAPEUTIC USE
PL2929880T3 (en) A therapeutic agent for treating a disease that has an inhibitory effect on a factor that inhibits macrophage migration
BR302014001194S1 (en) Medical Applied Configuration
BR302014001193S1 (en) Medical Applied Configuration
BR302014001192S1 (en) Medical Applied Configuration
FR3005394B1 (en) EARMUFFS.
BR302013000449S1 (en) CONFIGURATION APPLIED ON FLOOR.
BR302013006606S1 (en) FOOT APPLIED CONFIGURATION FOR FURNITURE.
BR302013006607S1 (en) FOOT APPLIED CONFIGURATION FOR FURNITURE.
BR302013000507S1 (en) HYDRAULIC BRAKE CONFIGURATION.
BR302013006049S1 (en) CONFIGURATION APPLIED ON SHOE
BR302013006050S1 (en) CONFIGURATION APPLIED ON SHOE
BR302013005933S1 (en) CONFIGURATION APPLIED ON SHOE
BR302013005932S1 (en) CONFIGURATION APPLIED ON SHOE
BR302013005526S1 (en) CONFIGURATION APPLIED ON SHOE
BR302013005288S1 (en) CONFIGURATION APPLIED ON SHOE
TH1501000240A (en) Components for plant disease control and their use for plant disease control.
BR302013004256S1 (en) CONFIGURATION APPLIED ON SHOE
BR302013003824S1 (en) CONFIGURATION APPLIED ON SHOE